Avtor/Urednik		Šmid, L; Lešničar, H; Zakotnik, B; Šoba, E; Budihna, M; Furlan, L; Žargi, M; Rudolf, Z
Naslov		Radiotherapy, combined with simultaneous chemotherapy with mitomycin C and bleomycin for inoperable head and neck cancer - preliminary report
Tip		članek
Vir		Int J Radiat Oncol Biol Phys
Vol. in št.		Letnik 32, št. 3
Leto izdaje		1995
Obseg		str. 769-75
Jezik		eng
Abstrakt		PURPOSE: Prospectively designed randomized clinical study was undertaken to assess the efficacy of simultaneous application of irradiation, Mitomycin C, and Bleomycin in treatment of patients with inoperable head and neck carcinoma. METHODS AND MATERIALS: Between March 1991 and October 1993, 49 patients with inoperable head and neck carcinoma were randomly assigned to receive either radiation therapy alone (group A) or radiotherapy combined with simultaneous application of Mitomycin C and Bleomycin (group B). Patients in both groups were irradiated five times weekly with 2 Gy to the total dose of 66-70 Gy. Chemotherapy regimen included intramuscular application of Bleomycin 5 units twice a week, with the planned dose being 70 units and Mitomycin C 15 mg/m2 applied intravenously after delivery of 9-10 Gy of irradiation. The application of Mitomycin C was planned to be repeated on last day of radiotherapy in the dose of 10 mg/m2. In attempt to enhance the effect of chemotherapeutic drugs, patients in group B received also Nicotinamide, Chlorpromazine, and Dicoumarol. RESULTS: The difference in complete response rate between both treatment groups (24 percent in group A and 63 percent in group B) was statistically significant (p = 0.015). The difference in response rate was much more pronounced in patients with oropharyngeal carcinoma only (18 percent in group A compared to 81 percent in group B; p = 0.0003), while for all other subgroups added together, there was observed no benefit of multidrug therapy. Median follow-up was 18 months. Disease-free survival of patients in group A (9 percent) was significantly lower then in group B (48 percent) (p = 0.001). The difference between both treatment groups was even greater in patients with oropharyngeal carcinoma only: disease-free survival of these patients in group B was 66 percent, while in group A, all recurred (p = 0.00001).(trunc.)
Deskriptorji		ANTINEOPLASTIC AGENTS, COMBINED CARCINOMA, SQUAMOUS CELL HEAD AND NECK NEOPLASMS ADULT AGED BLEOMYCIN CHLORPROMAZINE COMBINED MODALITY THERAPY DICUMAROL FOLLOW-UP STUDIES MIDDLE AGE MITOMYCIN C NIACINAMIDE PROSPECTIVE STUDIES RADIOTHERAPY DOSAGE